Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

Risk Factors and Predictive Score for Bacteremic Biliary Tract Infections Due to Enterococcus faecalis and Enterococcus faecium: a Multicenter Cohort Study from the PROBAC Project

  • Mussa, Marco
  • Martínez Pérez-Crespo, Pedro María
  • Lopez Cortes, Luis Eduardo
  • Retamar Gentil, Pilar
  • Sousa Dominguez, Adrián
  • Goikoetxea Aguirre, Ane Josune
  • Reguera Iglesias, José María
  • León Jiménez, Eva
  • Fernández Natal, Isabel
  • Armiñanzas Castillo, Carlos
  • Boix Palop, Lucía
  • Cuquet Pedragosa, Jordi
  • Morán Rodríguez, Miguel Ángel
  • Fernandez Suarez, Jonathan
  • del Arco Jiménez, Alfonso
  • Jóver Saenz, Alfredo
  • Bahamonde Carrasco, Alberto
  • Galán Sánchez, Fátima
  • Sánchez Calvo, Juan Manuel
  • Smithson Amat, Alejandro
  • Vinuesa García, David
  • Sánchez Porto, Antonio
  • López Hernández, Inmaculada
  • Rodríguez Baño, Jesús
  • Lanz García, Joaquín
  • Montejo, Miguel
  • Pérez Rodríguez, María Teresa
  • Corzo Delgado, Enrique
  • Fariñas, Carmen
  • Arias Temprano, Marta
  • Martín Aspas, Andrés
  • Gea Lázaro, Isabel
  • Guzmán García, Marcos
  • Canueto Quintero, Jesús
  • Reche, Isabel María
  • Pérez Camacho, Inés
  • Merino de Lucas, Esperanza
  • Natera Kindelán, Clara
Biliary-tract bloodstream infections (BT-BSI) caused by Enterococcus faecalis and E. faecium are associated with inappropriate empirical treatment and worse outcomes compared to other etiologies. The objective of this study was to investigate the risk factors for enterococcal BT-BSI. Patients with BT-BSI from the PROBAC cohort, including consecutive patients with BSI in 26 Spanish hospitals between October 2016 and March 2017, were selected; episodes caused by E. faecalis or E. faecium and other causes were compared. Independent predictors for enterococci were identified by logistic regression, and a predictive score was developed. Eight hundred fifty episodes of BT-BSI were included; 73 (8.5%) were due to target Enterococcus spp. (48 [66%] were E. faecium and 25 [34%] E. faecalis). By multivariate analysis, the variables independently associated with Enterococcus spp. were (OR; 95% confidence interval): cholangiocarcinoma (4.48;1.32 to 15.25), hospital acquisition (3.58;2.11 to 6.07), use of carbapenems in the previous month (3.35;1.45 to 7.78), biliary prosthesis (2.19;1.24 to 3.90), and moderate or severe chronic kidney disease (1.55;1.07 to 2.26). The AUC of the model was 0.74 [95% CI0.67 to 0.80]. A score was developed, with 7, 6, 5, 4, and 2 points for these variables, respectively, with a negative predictive value of 95% for a score # 6. A model, including cholangiocarcinoma, biliary prosthesis, hospital acquisition, previous carbapenems, and chronic kidney disease showed moderate prediction ability for enterococcal BT-BSI. Although the score will need to be validated, this information may be useful for deciding empirical therapy in biliary tract infections when bacteremia is suspected. IMPORTANCE Biliary tract infections are frequent, and a significant cause of morbidity and mortality. Bacteremia is common in these infections, particularly in the elderly and patients with cancer. Inappropriate empirical treatment has been associated with increased risk of mortality in bacteremic cholangitis, and the probability of receiving inactive empirical treatment is higher in episodes caused by enterococci. This is because many of the antimicrobial agents recommended in guidelines for biliary tract infections lack activity against these organisms. To the best of our knowledge, this is the first study analyzing the predictive factors for enterococcal BT-BSI and deriving a predictive score., 8 páginas
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A comprehensive, predictive mortality score for patients with bloodstream infections (PROBAC): a prospective, multicentre cohort study

  • Rosa-Riestra, Sandra de la
  • López-Hernández, Inmaculada
  • Pérez-Rodríguez, María Teresa
  • Sousa, Adrián
  • Goikoetxea-Aguirre, Josune
  • Reguera Iglesias, José María
  • León, Eva
  • Armiñanzas Castillo, Carlos
  • Sánchez Gómez, Leticia
  • Fernández-Natal, Isabel
  • Fernández Suárez, Jonathan
  • Boix-Palop, Lucía
  • Cuquet Pedragosa, Jordi
  • Jover-Sáenz, Alfredo
  • Sánchez Calvo, Juan Manuel
  • Martín-Aspas, Andrés
  • Natera Kindelán, Clara
  • Del Arco Jiménez, Alfonso
  • Bahamonde Carrasco, Alberto
  • Amat, Alejandro Smithson
  • Vinuesa García, David
  • Martínez Pérez-Crespo, Pedro María
  • López-Cortés, Luis Eduardo
  • Rodríguez-Baño, Jesús
Bloodstream infections (BSI) are an important cause of mortality, although they show heterogeneity depending on patients and aetiological factors. Comprehensive and specific mortality scores for BSI are scarce. The objective of this study was to develop a mortality predictive score in BSI based on a multicentre prospective cohort., This work was financed by grants from Plan Nacional de I + D + i 2013–2016, Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades (PI16/01432); Spanish Network for Research in Infectious Diseases (REIPI) (RD16/0016/0001; RD16/0016/0008) and cofinanced by European Development Regional Fund ‘A way to achieve Europe’, Operative Program Intelligent Growth 2014e2020., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Development and validation of a predictive mortality scoring model for bloodstream infections due to Escherichia coli in the PROBAC cohort

  • Olivares Navarro, Paula
  • Pérez-Rodríguez, María Teresa
  • Goikoetxea-Agirre, Ane Josune
  • Reguera Iglesias, José María
  • León, Eva
  • Mantecón, María Ángeles
  • Pulido-Navazo, Ángeles
  • Boix-Palop, Lucía
  • Retamar Gentil, Pilar
  • Armiñanzas Castillo, Carlos
  • Fernández-Natal, Isabel
  • Jover-Sáenz, Alfredo
  • Arco-Jiménez, Alfonso del
  • Fernández Suárez, Jonathan
  • Martín-Aspas, Andrés
  • Smithson Amat, Alejandro
  • Bahamonde-Carrasco, Alberto
  • Natera Kindelán, Clara
  • Martínez Pérez-Crespo, Pedro María
  • López-Hernández, Inmaculada
  • López-Cortés, Luis Eduardo
  • Rodríguez-Baño, Jesús
[Introduction] Escherichia coli is the most frequent cause of bacteraemia and has a major impact on morbidity and mortality. The aim of this study is to define and internally validate a predictive risk score of 30-day all-cause mortality., [Methods] A prospective, multicentre, cohort study conducted in 26 Spanish hospitals between October 2016 and March 2017 was performed. All monomicrobial E. coli bloodstream infections (BSIs) were included. The primary outcome was 30-day all-cause mortality. Cases were randomized to a derivation cohort (DC) and a validation cohort (VC). The predictive score was calculated from a multivariable model performed by logistic regression in the DC and subsequently applied to the VC. The predictive ability of the model was estimated by calculating the area under the ROC curve (AUROC) and the goodness of fit by Hosmer–Lemeshow test and calibration plot., [Results] Overall, 1435 cases were included in the DC and 715 in the VC. The final multivariable model for mortality in DC included (adjusted OR; 95% CI) age over 55 years (2.10; 1.01–4.36), dementia (2.08; 1.24–3.50), liver disease (1.81; 0.99–3.28), healthcare-associated acquisition (2.29; 1.52–3.44), Pitt index > 3 (3.59; 2.30–5.61), SOFA ≥ 2 (1.66; 1.04–2.64), and urinary tract source (0.37; 0.24–0.56). The predictive score showed an AUROC of 0.78 (95% CI 0.74–0.83) in the DC and 0.78 (95% CI 0.73–0.84) in the VC., [Conclusion] We developed and internally validated a predictive scoring model to identify patients with E. coli bacteraemia at high and low risk of crude mortality on day 30 of BSI., Funding for open access publishing: Universidad de Sevilla/CBUA. This research was supported by grants from Plan Nacional de I + D + i 2013–2016, Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de la Cultura, Innovación y Universidades (PI16/01432); the Spanish Network for Research in Infectious Diseases (REIPI) (RD16/0016/0001; RD16/0016/0008); and co-financed by the European Regional Development Fund under the ‘A way to achieve Europe’ Operational Program for Intelligent Growth 2014–2020., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

External validation of the predictive ability of Charson, SOFA, Pitt, INCREMENT-ESBL and bloodstream infection mortality Risk for 30-day-mortality in bacteraemia using the PROBAC cohort data

  • Rosa-Riestra, Sandra de la
  • Gutiérrez-Gutiérrez, Belén
  • López-Hernández, Inmaculada
  • Pérez-Rodríguez, María Teresa
  • Goikoetxea-Aguirre, Josune
  • Plata, Antonio
  • León, Eva
  • Fariñas Álvarez, María Carmen
  • Fernández-Natal, Isabel
  • Fernández Suárez, Jonathan
  • Boix-Palop, Lucía
  • Cuquet Pedragosa, Jordi
  • Jover-Sáenz, Alfredo
  • Sánchez Calvo, Juan Manuel
  • Martín-Aspas, Andrés
  • Natera Kindelán, Clara
  • Arco-Jiménez, Alfonso del
  • Martínez Pérez-Crespo, Pedro María
  • López-Cortés, Luis Eduardo
  • Rodríguez-Baño, Jesús
[Introduction] The development of predictive mortality scores for bacteraemia is fundamental for identifying patients in whom increasing our management efforts. However, it is necessary to assess the validity of the results obtained when they are applied to new cohorts., [Methods] We evaluated the ability of different scales (Charlson, also age-adjusted Charlson and updated Charlson, SOFA, Pitt, INCREMENT-ESBL and BSIMRS) to predict 30-day mortality in bacteraemia through the AUROC and calibration plots. The scales were applied to specific patient from PROBAC cohort (prospective, multicentre with bacteraemia of any aetiology) according to the population in which the scale was originally developed. We also applied the recently developed PROBAC score (this time applied to the entire PROBAC cohort, rather than only to patients who did not die within 48 h of blood culture collection as in the original development of the scale)., [Results] After applying Charlson, age-adjusted Charlson, updated Charlson, SOFA, Pitt and PROBAC to the entire PROBAC cohort, we obtained AUROC values: 0.60 (95% CI: 0.58–0.62); 0.62 (95% CI: 0.60–0.64); 0.60 (95% CI: 0.58–0.62); 0.69 (95% CI: 0.66–0.71); 0.71 (95% CI: 0.69–0.82) and 0.80 (95% CI: 0.79–0.81), respectively. INCREMENT-ESBL was applied only to gram negative bacteraemia yielding 0.81 (95% CI: 0.79–0.82) and BSIMRS to gram negative bacteraemia who received adequate empirical antibiotic yielding 0.72 (95% CI: 0.70–0.75)., [Conclusions] Scores that have been developed in bacteraemia cohorts and have been used for the prediction of short-term mortality were found to be better at predicting mortality in our analysis., This work was financed by grants from Plan Nacional de I + D + i 2013– 2016, Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades (PI16/01432); Spanish Network for Research in Infectious Diseases (REIPI) (RD16/0016/0001; RD16/0016/0008) and cofinanced by European Development Regional Fund ‘A way to achieve Europe’, Operative Program Intelligent Growth 2014e2020., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Datos de investigación Set de datos (Dataset)

External validation of the predictive ability of Charson, SOFA, Pitt, INCREMENT-ESBL and bloodstream infection mortality Risk for 30-day-mortality in bacteraemia using the PROBAC cohort data [Dataset]

  • Rosa-Riestra, Sandra de la
  • Gutiérrez-Gutiérrez, Belén
  • López-Hernández, Inmaculada
  • Pérez-Rodríguez, María Teresa
  • Goikoetxea-Aguirre, Josune
  • Plata, Antonio
  • León, Eva
  • Fariñas Álvarez, María Carmen
  • Fernández-Natal, Isabel
  • Fernández Suárez, Jonathan
  • Boix-Palop, Lucía
  • Cuquet Pedragosa, Jordi
  • Jover-Sáenz, Alfredo
  • Sánchez Calvo, Juan Manuel
  • Martín-Aspas, Andrés
  • Natera Kindelán, Clara
  • Arco-Jiménez, Alfonso del
  • Martínez Pérez-Crespo, Pedro María
  • López-Cortés, Luis Eduardo
  • Rodríguez-Baño, Jesús
The development of predictive mortality scores for bacteraemia is fundamental for identifying patients in whom increasing our management efforts. However, it is necessary to assess the validity of the results obtained when they are applied to new cohorts. We evaluated the ability of different scales (Charlson, also age-adjusted Charlson and updated Charlson, SOFA, Pitt, INCREMENT-ESBL and BSIMRS) to predict 30-day mortality in bacteraemia through the AUROC and calibration plots. The scales were applied to specific patient from PROBAC cohort (prospective, multicentre with bacteraemia of any aetiology) according to the population in which the scale was originally developed. We also applied the recently developed PROBAC score (this time applied to the entire PROBAC cohort, rather than only to patients who did not die within 48 h of blood culture collection as in the original development of the scale). After applying Charlson, age-adjusted Charlson, updated Charlson, SOFA, Pitt and PROBAC to the entire PROBAC cohort, we obtained AUROC values: 0.60 (95% CI: 0.58–0.62); 0.62 (95% CI: 0.60–0.64); 0.60 (95% CI: 0.58–0.62); 0.69 (95% CI: 0.66–0.71); 0.71 (95% CI: 0.69–0.82) and 0.80 (95% CI: 0.79–0.81), respectively. INCREMENT-ESBL was applied only to gram negative bacteraemia yielding 0.81 (95% CI: 0.79–0.82) and BSIMRS to gram negative bacteraemia who received adequate empirical antibiotic yielding 0.72 (95% CI: 0.70–0.75). Scores that have been developed in bacteraemia cohorts and have been used for the prediction of short-term mortality were found to be better at predicting mortality in our analysis., This work was financed by grants from Plan Nacional de I + D + i 2013– 2016, Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades (PI16/01432); Spanish Network for Research in Infectious Diseases (REIPI) (RD16/0016/0001; RD16/0016/0008) and cofinanced by European Development Regional Fund ‘A way to achieve Europe’, Operative Program Intelligent Growth 2014e2020., Peer reviewed